General Information of Drug (ID: DM7OKQV)

Drug Name
Cholic Acid Drug Info
Synonyms
cholic acid; 81-25-4; Cholalic acid; cholate; Cholalin; Colalin; Cholsaeure; NSC-6135; Cholic acid, 5beta-; 3alpha,7alpha,12alpha-Trihydroxy-5beta-cholanic acid; 3alpha,7alpha,12alpha-Trihydroxy-5beta-cholan-24-oic acid; UNII-G1JO7801AE; HSDB 982; (R)-4-((3R,5S,7R,8R,9S,10S,12S,13R,14S,17R)-3,7,12-Trihydroxy-10,13-dimethylhexadecahydro-1H-cyclopenta[a]phenanthren-17-yl)pentanoic acid; Cholic acid [USAN]; 3,7,12-Trihydroxycholanic acid; G1JO7801AE; CHEMBL205596; CHEBI:16359; NSC6135; BHQCQFFYRZLCQQ-OELDTZBJSA-N
Indication
Disease Entry ICD 11 Status REF
Cholelithiasis DC11 Approved [1]
Peroxisomal disorder 5C57 Approved [2]
Synthesis disorder 5C52-5C59 Approved [2]
Cross-matching ID
PubChem CID
221493
ChEBI ID
CHEBI:16359
CAS Number
CAS 81-25-4
TTD Drug ID
DM7OKQV
VARIDT Drug ID
DR00657
INTEDE Drug ID
DR0314
ACDINA Drug ID
D00943

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
DTP
DME
DOT
Drug Status:
Approved Drug(s)
Clinical Trial Drug(s)
Investigative Drug(s)
Discontinued Drug(s)
Drug(s) Targeting Phospholipase A2 (PLA2G1B)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Miltefosine DMND304 Chronic urticaria Approved [14]
Clocortolone DM9ZMQH Exanthem Approved [15]
Clobetasol DMUXP52 Rosacea ED90.0 Approved [16]
Diflorasone DMI9PRJ Exanthem Approved [17]
AllerB DM78DOT Allergy 4A80-4A85 Phase 2b [18]
URSOLIC ACID DM4SOAW Metabolic syndrome x 5C50-5D2Z Phase 2 [19]
MANOALIDE DMB4A8I Arthritis FA20 Phase 2 [20]
MRX-4 DMQZWYE Allergic rhinitis CA08.0 Phase 2 [21]
MRX-6 DMLVQKF Contact dermatitis EK0Z Phase 2 [22]
Varespladib DM5JJ83 Snakebite N.A. Phase 2 [23]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Targeting Ferrochelatase (FECH)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Methyl aminolevulinate DMIUX3D Acne vulgaris ED80 Approved [24]
N-Methylmesoporphyrin Containing Copper DMKZL5H Discovery agent N.A. Investigative [3]
Lead acetate DML0GZ2 Discovery agent N.A. Investigative [25]
N-Methylmesoporphyrin DM4FMZP Discovery agent N.A. Investigative [3]
Drug Name Drug ID Indication ICD 11 Highest Status REF
PACTIMIBE DM0NZDT Arteriosclerosis BD40 Phase 2/3 [26]
K-604 DMQVN6P Arteriosclerosis BD40 Phase 2 [27]
Eldacimibe DML7WP0 Hyperlipidaemia 5C80 Phase 2 [28]
GR148672X DM7W6YN Acute lymphoblastic leukaemia 2A85 Clinical trial [29]
Avasimibe DMFG4OM Peripheral vascular disease BD4Z Discontinued in Phase 3 [30]
E-5324 DM562BM Hyperlipidaemia 5C80 Discontinued in Phase 2 [31]
RP-64477 DMTQ3BS Hyperlipidaemia 5C80 Discontinued in Phase 2 [32]
CI-976 DMBO28J Hyperlipidaemia 5C80 Discontinued in Phase 2 [33]
CL-283796 DM7LIDT Hyperlipidaemia 5C80 Discontinued in Phase 2 [34]
Eflucimibe DMZXRF2 Hyperlipidaemia 5C80 Discontinued in Phase 2 [28]
⏷ Show the Full List of 10 Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Doxorubicin DMVP5YE Acute myelogenous leukaemia 2A41 Approved [35]
Methotrexate DM2TEOL Anterior urethra cancer Approved [36]
Folic Acid DMEMBJC Colorectal carcinoma Approved [37]
Fluorouracil DMUM7HZ Adenocarcinoma 2D40 Approved [38]
Dinoprostone DMTYOPD Medical abortion JA00.1Z Approved [39]
Cisplatin DMRHGI9 Adenocarcinoma 2D40 Approved [40]
Acetaminophen DMUIE76 Allergic rhinitis CA08.0 Approved [41]
Sulfasalazine DMICA9H Irritable bowel syndrome DD91.0 Approved [42]
Etoposide DMNH3PG Acute myelogenous leukaemia 2A41 Approved [43]
Oxaliplatin DMQNWRD Adenocarcinoma 2D40 Approved [44]
⏷ Show the Full List of 10 Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Doxorubicin DMVP5YE Acute myelogenous leukaemia 2A41 Approved [45]
Methotrexate DM2TEOL Anterior urethra cancer Approved [46]
Folic Acid DMEMBJC Colorectal carcinoma Approved [47]
Fluorouracil DMUM7HZ Adenocarcinoma 2D40 Approved [48]
Cisplatin DMRHGI9 Adenocarcinoma 2D40 Approved [49]
Progesterone DMUY35B Amenorrhea GA20.0 Approved [50]
Tamoxifen DMLB0EZ Breast cancer 2C60-2C65 Approved [51]
Estradiol DMUNTE3 Acne vulgaris ED80 Approved [50]
Sulfasalazine DMICA9H Irritable bowel syndrome DD91.0 Approved [52]
Imatinib DM7RJXL Acute lymphoblastic leukaemia 2A85 Approved [53]
⏷ Show the Full List of 10 Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Methotrexate DM2TEOL Anterior urethra cancer Approved [54]
Dinoprostone DMTYOPD Medical abortion JA00.1Z Approved [9]
Imatinib DM7RJXL Acute lymphoblastic leukaemia 2A85 Approved [55]
Etoposide DMNH3PG Acute myelogenous leukaemia 2A41 Approved [56]
Sorafenib DMS8IFC Adenocarcinoma 2D40 Approved [55]
Pravastatin DM6A0X7 Adult acute monocytic leukemia Approved [57]
Mycophenolate mofetil DMPQAGE Hepatosplenic T-cell lymphoma Approved [58]
Atorvastatin DMF28YC Acute coronary syndrome BA41 Approved [59]
Cerivastatin DMXCM7H Hyperlipidaemia 5C80 Approved [60]
PITAVASTATIN CALCIUM DM1UJO0 Dyslipidemia 5C80-5C81 Approved [57]
⏷ Show the Full List of 10 Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Methotrexate DM2TEOL Anterior urethra cancer Approved [61]
Folic Acid DMEMBJC Colorectal carcinoma Approved [62]
Fluorouracil DMUM7HZ Adenocarcinoma 2D40 Approved [63]
Dinoprostone DMTYOPD Medical abortion JA00.1Z Approved [64]
Zidovudine DM4KI7O Human immunodeficiency virus infection 1C62 Approved [6]
Prasterone DM67VKL Chronic obstructive pulmonary disease CA22 Approved [65]
Irinotecan DMP6SC2 Adenocarcinoma 2D40 Approved [66]
Mercaptopurine DMTM2IK Acute lymphoblastic leukaemia 2A85 Approved [67]
Glutathione DMAHMT9 Human immunodeficiency virus infection 1C62 Approved [68]
Ganciclovir DM1MBYQ Cytomegalovirus infection 1D82 Approved [6]
⏷ Show the Full List of 10 Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Deoxycholic acid DM3GYAL Subcutaneous fat disorder EF02 Approved [69]
Taurocholic Acid DM2LZ8F Type-2 diabetes 5A11 Phase 1/2 [70]
Sodium taurocholate DM3GO0J Type-2 diabetes 5A11 Phase 1/2 [70]
glycodeoxycholic acid DM1XEJV Discovery agent N.A. Investigative [4]
Drug Name Drug ID Indication ICD 11 Highest Status REF
Methotrexate DM2TEOL Anterior urethra cancer Approved [71]
Dinoprostone DMTYOPD Medical abortion JA00.1Z Approved [72]
Imatinib DM7RJXL Acute lymphoblastic leukaemia 2A85 Approved [73]
Atorvastatin DMF28YC Acute coronary syndrome BA41 Approved [74]
PITAVASTATIN CALCIUM DM1UJO0 Dyslipidemia 5C80-5C81 Approved [75]
Rosuvastatin DMMIQ7G Arteriosclerosis BD40 Approved [76]
Saquinavir DMG814N Human immunodeficiency virus infection 1C62 Approved [77]
Enalapril DMNFUZR Congestive heart failure BD10 Approved [78]
Liothyronine DM6IR3P Congenital hypothyroidism Approved [79]
Labetalol DMK8U72 Hypertension BA00-BA04 Approved [80]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Metabolized By Sulfotransferase 1A1 (SULT1A1)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Progesterone DMUY35B Amenorrhea GA20.0 Approved [81]
Tamoxifen DMLB0EZ Breast cancer 2C60-2C65 Approved [82]
Estradiol DMUNTE3 Acne vulgaris ED80 Approved [83]
Acetaminophen DMUIE76 Allergic rhinitis CA08.0 Approved [84]
Aspirin DM672AH Acute coronary syndrome BA41 Approved [85]
Warfarin DMJYCVW Atrial fibrillation BC81.3 Approved [86]
Liothyronine DM6IR3P Congenital hypothyroidism Approved [87]
Epinephrine DM3KJBC Acute asthma CA23 Approved [88]
Benzyl alcohol DMBVYDI Head and body lice 1G00.0 Approved [89]
Teicoplanin DMAQ2LK Bacterial infection 1A00-1C4Z Approved [90]
⏷ Show the Full List of 10 Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Lopinavir DMITQS0 Human immunodeficiency virus infection 1C62 Approved [91]
Sulfinpyrazone DMEV954 Gout FA25 Approved [92]
Probenecid DMMFWOJ Acute gonococcal cervicitis Approved [93]
Docetaxel DMDI269 Advanced cancer 2A00-2F9Z Approved [94]
Methotrexate DM2TEOL Anterior urethra cancer Approved [95]
Arsenic trioxide DM61TA4 Acute lymphoblastic leukaemia 2A85 Approved [96]
Epirubicin DMPDW6T Solid tumour/cancer 2A00-2F9Z Approved [97]
Cisplatin DMRHGI9 Adenocarcinoma 2D40 Approved [98]
Acetaminophen DMUIE76 Allergic rhinitis CA08.0 Approved [99]
Phenobarbital DMXZOCG Cluster headache 8A81.0 Approved [100]
⏷ Show the Full List of 10 Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Enalapril DMNFUZR Congestive heart failure BD10 Approved [101]
Lovastatin DM9OZWQ Arteriosclerosis BD40 Approved [102]
Bosentan DMIOGBU Pulmonary arterial hypertension BB01.0 Approved [103]
Repaglinide DM5SXUV Diabetic complication 5A2Y Approved [104]
Methotrexate DM2TEOL Anterior urethra cancer Approved [105]
Simvastatin DM30SGU Arteriosclerosis BD40 Approved [106]
Ursodeoxycholic acid DMCUT21 Cholelithiasis DC11 Approved [107]
Hydroxyurea DMOQVU9 Chronic myelogenous leukaemia 2A20.0 Approved [108]
Irinotecan DMP6SC2 Adenocarcinoma 2D40 Approved [109]
Aspirin DM672AH Acute coronary syndrome BA41 Approved [110]
⏷ Show the Full List of 10 Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Verapamil DMA7PEW Angina pectoris BA40 Approved [111]
Vidarabine DM0N85H Hepatosplenic T-cell lymphoma Approved [111]
Beta-carotene DM0RXBT Vitamin deficiency 5B55-5B71 Approved [112]
Fulvestrant DM0YZC6 Breast cancer 2C60-2C65 Approved [113]
Secobarbital DM14RF5 Epilepsy 8A60-8A68 Approved [114]
Etidronic acid DM1XHYJ Bone Paget disease Approved [111]
Tiaprofenic acid DM23D7J Osteoarthritis FA00-FA05 Approved [111]
Bromperidol DM24XYQ Schizophrenia 6A20 Approved [111]
Simvastatin DM30SGU Arteriosclerosis BD40 Approved [115]
Deoxycholic acid DM3GYAL Subcutaneous fat disorder EF02 Approved [13]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Affected By Cytochrome P450 3A4 (CYP3A4)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Eplerenone DMF0NQR Heart failure BD10-BD13 Approved [116]
Cannabidiol DM0659E Dravet syndrome 8A61.11 Approved [117]
Isotretinoin DM4QTBN Acne vulgaris ED80 Approved [118]
Voriconazole DMAOL2S Aspergillosis 1F20 Approved [119]
Proguanil DMBL79I Malaria 1F40-1F45 Approved [120]
Ivermectin DMDBX5F Intestinal strongyloidiasis due to nematode parasite 1F6B Approved [120]
Loratadine DMF3AN7 Allergy 4A80-4A85 Approved [121]
Nelfinavir mesylate DMFX6G8 N. A. N. A. Approved [122]
Capsaicin DMGMF6V Back pain ME84.Z Approved [123]
Axitinib DMGVH6N Renal cell carcinoma 2C90 Approved [124]
⏷ Show the Full List of 10 Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Paclitaxel DMLB81S Breast carcinoma Approved [98]
Methotrexate DM2TEOL Anterior urethra cancer Approved [125]
Etoposide DMNH3PG Acute myelogenous leukaemia 2A41 Approved [126]
Calcipotriol DM03CP7 Psoriasis EA90 Approved [127]
Cannabidiol DM0659E Dravet syndrome 8A61.11 Approved [128]
Fulvestrant DM0YZC6 Breast cancer 2C60-2C65 Approved [129]
Hydrogen peroxide DM1NG5W Infectious disease 1A00-CA43.1 Approved [130]
Prednisone DM2HG4X Acute asthma CA23 Approved [131]
Sulindac DM2QHZU Acute myelogenous leukaemia 2A41 Approved [132]
Simvastatin DM30SGU Arteriosclerosis BD40 Approved [133]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Affected By Bile salt export pump (ABCB11)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Glimepiride DM5FSJA Diabetic complication 5A2Y Approved [134]
Ezetimibe DM7A8TW Atherosclerosis BD40 Approved [135]
Glipizide DMZA5PQ Diabetic complication 5A2Y Approved [135]
Bosentan DMIOGBU Pulmonary arterial hypertension BB01.0 Approved [103]
Indinavir DM0T3YH Human immunodeficiency virus infection 1C62 Approved [134]
Ofloxacin DM0VQN3 Acute gonococcal cervicitis Approved [135]
Primidone DM0WX6I Epilepsy 8A60-8A68 Approved [136]
Gefitinib DM15F0X Colon adenocarcinoma Approved [134]
Drospirenone DM1A9W3 Acne vulgaris ED80 Approved [137]
Nitrendipine DM21C09 Hypertension BA00-BA04 Approved [134]
⏷ Show the Full List of 10 Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Clavulanate DM2FGRT Bacteremia 1A73 Approved [138]
Methotrexate DM2TEOL Anterior urethra cancer Approved [139]
Deoxycholic acid DM3GYAL Subcutaneous fat disorder EF02 Approved [11]
obeticholic acid DM3Q1SM Primary biliary cholangitis DB96.1 Approved [140]
Tretinoin DM49DUI Acne vulgaris ED80 Approved [141]
Panobinostat DM58WKG Chronic graft versus host disease Approved [142]
Rifampicin DM5DSFZ Non-insulin dependent diabetes 5A11 Approved [143]
Valproate DMCFE9I Epilepsy 8A60-8A68 Approved [144]
Ursodeoxycholic acid DMCUT21 Cholelithiasis DC11 Approved [11]
Niclosamide DMJAGXQ Cestodes infection 1F70-1F76 Approved [145]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Affected By Cytochrome P450 7A1 (CYP7A1)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Calcipotriol DM03CP7 Psoriasis EA90 Approved [127]
Clavulanate DM2FGRT Bacteremia 1A73 Approved [138]
Methotrexate DM2TEOL Anterior urethra cancer Approved [146]
Deoxycholic acid DM3GYAL Subcutaneous fat disorder EF02 Approved [12]
obeticholic acid DM3Q1SM Primary biliary cholangitis DB96.1 Approved [147]
Troglitazone DM3VFPD Diabetic complication 5A2Y Approved [148]
Tretinoin DM49DUI Acne vulgaris ED80 Approved [141]
Nefazodone DM4ZS8M Major depressive disorder 6A70.3 Approved [149]
Rifampicin DM5DSFZ Non-insulin dependent diabetes 5A11 Approved [150]
Calcitriol DM8ZVJ7 Congenital alopecia LC30 Approved [151]
⏷ Show the Full List of 10 Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Clavulanate DM2FGRT Bacteremia 1A73 Approved [138]
obeticholic acid DM3Q1SM Primary biliary cholangitis DB96.1 Approved [147]
Troglitazone DM3VFPD Diabetic complication 5A2Y Approved [152]
Tretinoin DM49DUI Acne vulgaris ED80 Approved [153]
Nefazodone DM4ZS8M Major depressive disorder 6A70.3 Approved [149]
Rifampicin DM5DSFZ Non-insulin dependent diabetes 5A11 Approved [100]
Ciclosporin DMAZJFX Graft-versus-host disease 4B24 Approved [154]
Lindane DMB8CNL Infestations of lice and scabies 1G00.Z Approved [155]
Valproate DMCFE9I Epilepsy 8A60-8A68 Approved [156]
Fenofibrate DMFKXDY Coronary atherosclerosis Approved [152]
⏷ Show the Full List of 10 Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Calcipotriol DM03CP7 Psoriasis EA90 Approved [127]
Sertraline DM0FB1J Coronary heart disease BA80.Z Approved [157]
Fulvestrant DM0YZC6 Breast cancer 2C60-2C65 Approved [158]
Hydrogen peroxide DM1NG5W Infectious disease 1A00-CA43.1 Approved [159]
Clavulanate DM2FGRT Bacteremia 1A73 Approved [138]
Imipramine DM2NUH3 Depression 6A70-6A7Z Approved [157]
Thioridazine DM35M8J Schizophrenia 6A20 Approved [160]
Deoxycholic acid DM3GYAL Subcutaneous fat disorder EF02 Approved [161]
Quercetin DM3NC4M Obesity 5B81 Approved [162]
Fluoxetine DM3PD2C Bipolar depression Approved [157]
⏷ Show the Full List of 10 Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Hydrogen peroxide DM1NG5W Infectious disease 1A00-CA43.1 Approved [130]
Clavulanate DM2FGRT Bacteremia 1A73 Approved [138]
Methotrexate DM2TEOL Anterior urethra cancer Approved [146]
Deoxycholic acid DM3GYAL Subcutaneous fat disorder EF02 Approved [11]
Quercetin DM3NC4M Obesity 5B81 Approved [162]
obeticholic acid DM3Q1SM Primary biliary cholangitis DB96.1 Approved [140]
Tretinoin DM49DUI Acne vulgaris ED80 Approved [163]
Rifampicin DM5DSFZ Non-insulin dependent diabetes 5A11 Approved [164]
Calcitriol DM8ZVJ7 Congenital alopecia LC30 Approved [165]
Leflunomide DMR8ONJ Arthritis FA20 Approved [166]
⏷ Show the Full List of 10 Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Pantothenic acid DM091H2 Vitamin deficiency 5B55-5B71 Approved [167]
Hydrogen peroxide DM1NG5W Infectious disease 1A00-CA43.1 Approved [130]
Deoxycholic acid DM3GYAL Subcutaneous fat disorder EF02 Approved [11]
Quercetin DM3NC4M Obesity 5B81 Approved [162]
obeticholic acid DM3Q1SM Primary biliary cholangitis DB96.1 Approved [140]
Rifampicin DM5DSFZ Non-insulin dependent diabetes 5A11 Approved [164]
Liothyronine DM6IR3P Congenital hypothyroidism Approved [168]
Calcitriol DM8ZVJ7 Congenital alopecia LC30 Approved [169]
Leflunomide DMR8ONJ Arthritis FA20 Approved [166]
Ciclosporin DMAZJFX Graft-versus-host disease 4B24 Approved [170]
⏷ Show the Full List of 10 Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Deoxycholic acid DM3GYAL Subcutaneous fat disorder EF02 Approved [11]
Valproate DMCFE9I Epilepsy 8A60-8A68 Approved [156]
Ursodeoxycholic acid DMCUT21 Cholelithiasis DC11 Approved [171]
Dexamethasone DMMWZET Acute adrenal insufficiency Approved [172]
Chenodiol DMQ8JIK Cholelithiasis DC11 Approved [11]
(+)-JQ1 DM1CZSJ Testicular cancer 2C80 Phase 1 [173]
Benzo(a)pyrene DMN7J43 N. A. N. A. Phase 1 [174]
tauroursodeoxycholic acid DMFKRQE Discovery agent N.A. Investigative [171]
⏷ Show the Full List of 8 Drug(s)
Drug(s) Affected By Bile acid receptor (NR1H4)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Hydrogen peroxide DM1NG5W Infectious disease 1A00-CA43.1 Approved [159]
Nitrendipine DM21C09 Hypertension BA00-BA04 Approved [175]
Deoxycholic acid DM3GYAL Subcutaneous fat disorder EF02 Approved [11]
Quercetin DM3NC4M Obesity 5B81 Approved [162]
Tretinoin DM49DUI Acne vulgaris ED80 Approved [176]
Nefazodone DM4ZS8M Major depressive disorder 6A70.3 Approved [149]
Nisoldipine DM7ISKJ Hypertension BA00-BA04 Approved [175]
Imatinib DM7RJXL Acute lymphoblastic leukaemia 2A85 Approved [177]
Ciclosporin DMAZJFX Graft-versus-host disease 4B24 Approved [154]
Lindane DMB8CNL Infestations of lice and scabies 1G00.Z Approved [178]
⏷ Show the Full List of 10 Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Clavulanate DM2FGRT Bacteremia 1A73 Approved [138]
Deoxycholic acid DM3GYAL Subcutaneous fat disorder EF02 Approved [11]
Quercetin DM3NC4M Obesity 5B81 Approved [162]
Tretinoin DM49DUI Acne vulgaris ED80 Approved [179]
Leflunomide DMR8ONJ Arthritis FA20 Approved [166]
Ciclosporin DMAZJFX Graft-versus-host disease 4B24 Approved [154]
Valproate DMCFE9I Epilepsy 8A60-8A68 Approved [156]
Bosentan DMIOGBU Pulmonary arterial hypertension BB01.0 Approved [103]
Cupric Sulfate DMP0NFQ Fungal infection 1F29-1F2F Approved [180]
Chenodiol DMQ8JIK Cholelithiasis DC11 Approved [11]
⏷ Show the Full List of 10 Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Warfarin DMJYCVW Atrial fibrillation BC81.3 Approved [181]
Fexofenadine DM17ONX Allergic rhinitis CA08.0 Approved [182]
Hydroxyurea DMOQVU9 Chronic myelogenous leukaemia 2A20.0 Approved [108]
Trospium chloride DM32XZT Discovery agent N.A. Approved [183]
Deoxycholic acid DM3GYAL Subcutaneous fat disorder EF02 Approved [11]
obeticholic acid DM3Q1SM Primary biliary cholangitis DB96.1 Approved [140]
Rifampicin DM5DSFZ Non-insulin dependent diabetes 5A11 Approved [164]
Calcitriol DM8ZVJ7 Congenital alopecia LC30 Approved [165]
Ciclosporin DMAZJFX Graft-versus-host disease 4B24 Approved [184]
Valproate DMCFE9I Epilepsy 8A60-8A68 Approved [156]
⏷ Show the Full List of 10 Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Chenodiol DMQ8JIK Cholelithiasis DC11 Approved [11]
Clavulanate DM2FGRT Bacteremia 1A73 Approved [138]
Deoxycholic acid DM3GYAL Subcutaneous fat disorder EF02 Approved [11]
Quercetin DM3NC4M Obesity 5B81 Approved [162]
obeticholic acid DM3Q1SM Primary biliary cholangitis DB96.1 Approved [140]
Ciclosporin DMAZJFX Graft-versus-host disease 4B24 Approved [154]
Lindane DMB8CNL Infestations of lice and scabies 1G00.Z Approved [178]
Valproate DMCFE9I Epilepsy 8A60-8A68 Approved [156]
Arsenic DMTL2Y1 N. A. N. A. Approved [185]
Ritonavir DMU764S Human immunodeficiency virus infection 1C62 Approved [186]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Affected By Sulfotransferase 2A1 (SULT2A1)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Hydrogen peroxide DM1NG5W Infectious disease 1A00-CA43.1 Approved [187]
Methotrexate DM2TEOL Anterior urethra cancer Approved [146]
Quercetin DM3NC4M Obesity 5B81 Approved [162]
Tretinoin DM49DUI Acne vulgaris ED80 Approved [188]
Isotretinoin DM4QTBN Acne vulgaris ED80 Approved [188]
Nefazodone DM4ZS8M Major depressive disorder 6A70.3 Approved [149]
Leflunomide DMR8ONJ Arthritis FA20 Approved [166]
Ciclosporin DMAZJFX Graft-versus-host disease 4B24 Approved [154]
Lindane DMB8CNL Infestations of lice and scabies 1G00.Z Approved [189]
Valproate DMCFE9I Epilepsy 8A60-8A68 Approved [190]
⏷ Show the Full List of 10 Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Hydrogen peroxide DM1NG5W Infectious disease 1A00-CA43.1 Approved [130]
Zidovudine DM4KI7O Human immunodeficiency virus infection 1C62 Approved [191]
Rifampicin DM5DSFZ Non-insulin dependent diabetes 5A11 Approved [164]
Arsenic trioxide DM61TA4 Acute lymphoblastic leukaemia 2A85 Approved [96]
Ibuprofen DM8VCBE Dysmenorrhea GA34.3 Approved [192]
Calcitriol DM8ZVJ7 Congenital alopecia LC30 Approved [193]
Cidofovir DMA13GD Cytomegalovirus infection 1D82 Approved [192]
Ciclosporin DMAZJFX Graft-versus-host disease 4B24 Approved [154]
Valproate DMCFE9I Epilepsy 8A60-8A68 Approved [144]
Ethanol DMDRQZU Chronic pain MG30 Approved [194]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Ferrochelatase (FECH) TTQ6VF4 HEMH_HUMAN Inhibitor [3]
Liver carboxylesterase (CES1) TTMF541 EST1_HUMAN Inhibitor [3]
Phospholipase A2 (PLA2G1B) TT9V5JH PA21B_HUMAN Inhibitor [3]

Drug Transporter (DTP)
DTP Name DTP ID UniProt ID MOA REF
Apical sodium-dependent bile acid transporter (SLC10A2) DT7JELC NTCP2_HUMAN Substrate [4]
Multidrug resistance-associated protein 2 (ABCC2) DTFI42L MRP2_HUMAN Substrate [5]
Multidrug resistance-associated protein 4 (ABCC4) DTCSGPB MRP4_HUMAN Substrate [6]
Organic anion transporting polypeptide 1A2 (SLCO1A2) DTE2B1D SO1A2_HUMAN Substrate [7]
Breast cancer resistance protein (ABCG2) DTI7UX6 ABCG2_HUMAN Substrate [8]
Organic anion transporting polypeptide 1B1 (SLCO1B1) DT3D8F0 SO1B1_HUMAN Substrate [9]

Drug-Metabolizing Enzyme (DME)
DME Name DME ID UniProt ID MOA REF
Sulfotransferase 1A1 (SULT1A1) Main DME DEYWLRK ST1A1_HUMAN Substrate [10]

Drug Off-Target (DOT)
DOT Name DOT ID UniProt ID Interaction REF
7-alpha-hydroxycholest-4-en-3-one 12-alpha-hydroxylase (CYP8B1) OTRI4UR1 CP8B1_HUMAN Gene/Protein Processing [11]
ATP-binding cassette sub-family C member 2 (ABCC2) OTJSIGV5 MRP2_HUMAN Gene/Protein Processing [11]
ATP-binding cassette sub-family C member 3 (ABCC3) OTC3IJV4 MRP3_HUMAN Gene/Protein Processing [11]
ATP-binding cassette sub-family G member 5 (ABCG5) OT1OMY93 ABCG5_HUMAN Gene/Protein Processing [11]
Bile acid receptor (NR1H4) OTWZLPTB NR1H4_HUMAN Gene/Protein Processing [11]
Bile salt export pump (ABCB11) OTRU7THO ABCBB_HUMAN Gene/Protein Processing [12]
Cytochrome P450 3A4 (CYP3A4) OTQGYY83 CP3A4_HUMAN Gene/Protein Processing [13]
Cytochrome P450 7A1 (CYP7A1) OT8Z5KLD CP7A1_HUMAN Gene/Protein Processing [12]
Fibroblast growth factor 19 (FGF19) OT2DVJWY FGF19_HUMAN Gene/Protein Processing [11]
G-protein coupled bile acid receptor 1 (GPBAR1) OT4BKEJ9 GPBAR_HUMAN Gene/Protein Processing [11]

References

1 Cholic acid FDA Label
2 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 609).
3 How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
4 Expression and transport properties of the human ileal and renal sodium-dependent bile acid transporter. Am J Physiol. 1998 Jan;274(1):G157-69.
5 Multiple pathways for fluoroquinolone secretion by human intestinal epithelial (Caco-2) cells. Br J Pharmacol. 2002 Mar;135(5):1263-75.
6 Human intestinal transporter database: QSAR modeling and virtual profiling of drug uptake, efflux and interactions. Pharm Res. 2013 Apr;30(4):996-1007.
7 Molecular and functional characterization of an organic anion transporting polypeptide cloned from human liver. Gastroenterology. 1995 Oct;109(4):1274-82.
8 Characterization of the role of ABCG2 as a bile acid transporter in liver and placenta. Mol Pharmacol. 2012 Feb;81(2):273-83.
9 Organic anion transporting polypeptide 1B1: a genetically polymorphic transporter of major importance for hepatic drug uptake. Pharmacol Rev. 2011 Mar;63(1):157-81.
10 Kinetic analysis of bile acid sulfation by stably expressed human sulfotransferase 2A1 (SULT2A1). Xenobiotica. 2010 Mar;40(3):184-94.
11 Potency of individual bile acids to regulate bile acid synthesis and transport genes in primary human hepatocyte cultures. Toxicol Sci. 2014 Oct;141(2):538-46. doi: 10.1093/toxsci/kfu151. Epub 2014 Jul 23.
12 The farnesoid X receptor controls gene expression in a ligand- and promoter-selective fashion. J Biol Chem. 2004 Mar 5;279(10):8856-61. doi: 10.1074/jbc.M306422200. Epub 2003 Dec 18.
13 Acetylated deoxycholic (DCA) and cholic (CA) acids are potent ligands of pregnane X (PXR) receptor. Toxicol Lett. 2017 Jan 4;265:86-96.
14 Novel antifungal agents, targets or therapeutic strategies for the treatment of invasive fungal diseases: a review of the literature (2005-2009). Rev Iberoam Micol. 2009 Mar 31;26(1):15-22.
15 Clocortolone pivalate: a paired comparison clinical trial of a new topical steroid in eczema/atopic dermatitis. Cutis. 1980 Jan;25(1):96-8.
16 Utilization of epidermal phospholipase A2 inhibition to monitor topical steroid action. Br J Dermatol. 1984 Jul;111 Suppl 27:195-203.
17 Structures from powders: diflorasone diacetate. Steroids. 2009 Jan;74(1):102-11.
18 Successful immunotherapy with T-cell epitope peptides of bee venom phospholipase A2 induces specific T-cell anergy in patients allergic to bee venom. J Allergy Clin Immunol. 1998 Jun;101(6 Pt 1):747-54.
19 Synthesis of benzoyl phenyl benzoates as effective inhibitors for phospholipase A2 and hyaluronidase enzymes. Bioorg Med Chem Lett. 2005 Sep 15;15(18):4100-4.
20 Manoalide, a phospholipase A2 inhibitor, inhibits arachidonate incorporation and turnover in brain phospholipids of the awake rat. Neurochem Res. 1998 Oct;23(10):1251-7.
21 Phospholipase A2, group IVA (cytosolic, calcium-dependent) (PLA2G4A). SciBX 1(41); doi:10.1038/scibx.2008.999. Nov. 13 2008
22 A novel treatment of contact dermatitis by topical application of phospholipase A2 inhibitor: a double-blind placebo-controlled pilot study. Int J Immunopathol Pharmacol. 2007 Jan-Mar;20(1):191-5.
23 Varespladib in the Treatment of Snakebite Envenoming: Development History and Preclinical Evidence Supporting Advancement to Clinical Trials in Patients Bitten by Venomous Snakes. Toxins (Basel). 2022 Nov 11;14(11):783.
24 Low-dose methotrexate enhances aminolevulinate-based photodynamic therapy in skin carcinoma cells in vitro and in vivo. Clin Cancer Res. 2009 May 15;15(10):3333-43.
25 Ferrochelatase, a novel target for photodynamic therapy of cancer. Oncol Rep. 1999 Nov-Dec;6(6):1439-42.
26 Novel indoline-based acyl-CoA:cholesterol acyltransferase inhibitor with antiperoxidative activity: improvement of physicochemical properties and b... J Med Chem. 2008 Aug 14;51(15):4823-33.
27 A selective ACAT-1 inhibitor, K-604, suppresses fatty streak lesions in fat-fed hamsters without affecting plasma cholesterol levels. Atherosclerosis. 2007 Apr;191(2):290-7.
28 Prospects for drug therapy for hyperlipoproteinaemia. Diabete Metab. 1995 Apr;21(2):139-46.
29 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2592).
30 New advances in lipid-modifying therapies for reducing cardiovascular risk. Cardiology. 2002;97(2):59-66.
31 Effect of the acyl-CoA:cholesterol acyltransferase inhibitor, E5324, on experimental atherosclerosis in rabbits. Atherosclerosis. 1994 Jun;107(2):187-201.
32 RP 64477: a potent inhibitor of acyl-coenzyme A:cholesterol O-acyltransferase with low systemic bioavailability. Biochem Pharmacol. 1996 Feb 23;51(4):413-21.
33 Acyl-coenzyme A:cholesterol-acyltransferase (ACAT) inhibitors modulate monocyte adhesion to aortic endothelial cells. Atherosclerosis. 1995 Jan 6;112(1):7-17.
34 ACAT inhibitors CL 283,546 and CL 283,796 reduce LDL cholesterol without affecting cholesterol absorption in African green monkeys. J Lipid Res. 1995 Jun;36(6):1199-210.
35 Involvement of the drug transporters p glycoprotein and multidrug resistance-associated protein Mrp2 in telithromycin transport. Antimicrob Agents Chemother. 2006 Jan;50(1):80-7.
36 Dose-dependent disposition of methotrexate in Abcc2 and Abcc3 gene knockout murine models. Drug Metab Dispos. 2011 Nov;39(11):2155-61.
37 Mammalian multidrug-resistance proteins (MRPs). Essays Biochem. 2011 Sep 7;50(1):179-207.
38 Enhancing chemosensitivity in oral squamous cell carcinoma by lentivirus vector-mediated RNA interference targeting EGFR and MRP2. Oncol Lett. 2016 Sep;12(3):2107-2114.
39 Multidrug resistance associated protein 2 mediates transport of prostaglandin E2. Liver Int. 2006 Apr;26(3):362-8.
40 Lentivirus-mediated RNAi silencing targeting ABCC2 increasing the sensitivity of a human nasopharyngeal carcinoma cell line against cisplatin. J Transl Med. 2008 Oct 4;6:55.
41 Effect of acetaminophen on expression and activity of rat liver multidrug resistance-associated protein 2 and P-glycoprotein. Biochem Pharmacol. 2004 Aug 15;68(4):791-8.
42 Small intestinal efflux mediated by MRP2 and BCRP shifts sulfasalazine intestinal permeability from high to low, enabling its colonic targeting. Am J Physiol Gastrointest Liver Physiol. 2009 Aug;297(2):G371-7.
43 Delineating the contribution of secretory transporters in the efflux of etoposide using Madin-Darby canine kidney (MDCK) cells overexpressing P-glycoprotein (Pgp), multidrug resistance-associated protein (MRP1), and canalicular multispecific organic anion transporter (cMOAT). Drug Metab Dispos. 2002 Apr;30(4):457-63.
44 Multidrug Resistance-Associated Protein 2 (MRP2) Mediated Transport of Oxaliplatin-Derived Platinum in Membrane Vesicles. PLoS One. 2015 Jul 1;10(7):e0130727.
45 Doxorubicin transport by RALBP1 and ABCG2 in lung and breast cancer. Int J Oncol. 2007 Mar;30(3):717-25.
46 Wild-type breast cancer resistance protein (BCRP/ABCG2) is a methotrexate polyglutamate transporter. Cancer Res. 2003 Sep 1;63(17):5538-43.
47 The effect of low pH on breast cancer resistance protein (ABCG2)-mediated transport of methotrexate, 7-hydroxymethotrexate, methotrexate diglutamate, folic acid, mitoxantrone, topotecan, and resveratrol in in vitro drug transport models. Mol Pharmacol. 2007 Jan;71(1):240-9.
48 Role of BCRP as a biomarker for predicting resistance to 5-fluorouracil in breast cancer. Cancer Chemother Pharmacol. 2009 May;63(6):1103-10.
49 Inhibiting the function of ABCB1 and ABCG2 by the EGFR tyrosine kinase inhibitor AG1478. Biochem Pharmacol. 2009 Mar 1;77(5):781-93.
50 Sterol transport by the human breast cancer resistance protein (ABCG2) expressed in Lactococcus lactis. J Biol Chem. 2003 Jun 6;278(23):20645-51.
51 The phytoestrogen genistein enhances multidrug resistance in breast cancer cell lines by translational regulation of ABC transporters. Cancer Lett. 2016 Jun 28;376(1):165-72.
52 Curcumin inhibits the activity of ABCG2/BCRP1, a multidrug resistance-linked ABC drug transporter in mice. Pharm Res. 2009 Feb;26(2):480-7.
53 Imatinib mesylate (STI571) is a substrate for the breast cancer resistance protein (BCRP)/ABCG2 drug pump. Blood. 2004 Nov 1;104(9):2940-2.
54 Preclinical Mouse Models To Study Human OATP1B1- and OATP1B3-Mediated Drug-Drug Interactions in Vivo. Mol Pharm. 2015 Dec 7;12(12):4259-69.
55 Contribution of OATP1B1 and OATP1B3 to the disposition of sorafenib and sorafenib-glucuronide. Clin Cancer Res. 2013 Mar 15;19(6):1458-66.
56 Identification of drugs and drug metabolites as substrates of multidrug resistance protein 2 (MRP2) using triple-transfected MDCK-OATP1B1-UGT1A1-MRP2 cells. Br J Pharmacol. 2012 Mar;165(6):1836-1847.
57 The effect of SLCO1B1*15 on the disposition of pravastatin and pitavastatin is substrate dependent: the contribution of transporting activity changes by SLCO1B1*15. Pharmacogenet Genomics. 2008 May;18(5):424-33.
58 Influence of SLCO1B1, 1B3, 2B1 and ABCC2 genetic polymorphisms on mycophenolic acid pharmacokinetics in Japanese renal transplant recipients. Eur J Clin Pharmacol. 2007 Dec;63(12):1161-9.
59 Rifampicin alters atorvastatin plasma concentration on the basis of SLCO1B1 521T>C polymorphism. Clin Chim Acta. 2009 Jul;405(1-2):49-52.
60 FDA Drug Development and Drug Interactions
61 Interaction of nonsteroidal anti-inflammatory drugs with multidrug resistance protein (MRP) 2/ABCC2- and MRP4/ABCC4-mediated methotrexate transport. J Pharmacol Exp Ther. 2007 Jan;320(1):229-35.
62 Analysis of methotrexate and folate transport by multidrug resistance protein 4 (ABCC4): MRP4 is a component of the methotrexate efflux system. Cancer Res. 2002 Jun 1;62(11):3144-50.
63 ATP-binding cassette C transporters in human pancreatic carcinoma cell lines. Upregulation in 5-fluorouracil-resistant cells. Pancreatology. 2009;9(1-2):136-44.
64 The human multidrug resistance protein MRP4 functions as a prostaglandin efflux transporter and is inhibited by nonsteroidal antiinflammatory drugs. Proc Natl Acad Sci U S A. 2003 Aug 5;100(16):9244-9.
65 Steroid and bile acid conjugates are substrates of human multidrug-resistance protein (MRP) 4 (ATP-binding cassette C4). Biochem J. 2003 Apr 15;371(Pt 2):361-7.
66 P-glycoprotein, but not multidrug resistance protein 4, plays a role in the systemic clearance of irinotecan and SN-38 in mice. Drug Metab Lett. 2010 Dec;4(4):195-201.
67 Polymorphisms in multidrug resistance-associated protein gene 4 is associated with outcome in childhood acute lymphoblastic leukemia. Blood. 2009 Aug 13;114(7):1383-6.
68 Role of glutathione in the multidrug resistance protein 4 (MRP4/ABCC4)-mediated efflux of cAMP and resistance to purine analogues. Biochem J. 2002 Feb 1;361(Pt 3):497-503.
69 Functional nanoparticles exploit the bile acid pathway to overcome multiple barriers of the intestinal epithelium for oral insulin delivery. Biomaterials. 2018 Jan;151:13-23.
70 Identification of a region of the ileal-type sodium/bile acid cotransporter interacting with a competitive bile acid transport inhibitor. Biochemistry. 2002 Dec 17;41(50):14916-24.
71 Interaction of methotrexate with organic-anion transporting polypeptide 1A2 and its genetic variants. J Pharmacol Exp Ther. 2006 Aug;318(2):521-9.
72 Localization of organic anion transporting polypeptide 4 (Oatp4) in rat liver and comparison of its substrate specificity with Oatp1, Oatp2 and Oatp3. Pflugers Arch. 2001 Nov;443(2):188-95.
73 Environmental and genetic factors affecting transport of imatinib by OATP1A2. Clin Pharmacol Ther. 2011 Jun;89(6):816-20.
74 Influence of the flavonoids apigenin, kaempferol, and quercetin on the function of organic anion transporting polypeptides 1A2 and 2B1. Biochem Pharmacol. 2010 Dec 1;80(11):1746-53.
75 Transporter-mediated influx and efflux mechanisms of pitavastatin, a new inhibitor of HMG-CoA reductase. J Pharm Pharmacol. 2005 Oct;57(10):1305-11.
76 Drug and bile acid transporters in rosuvastatin hepatic uptake: function, expression, and pharmacogenetics. Gastroenterology. 2006 May;130(6):1793-806.
77 Human organic anion-transporting polypeptide OATP-A (SLC21A3) acts in concert with P-glycoprotein and multidrug resistance protein 2 in the vectorial transport of Saquinavir in Hep G2 cells. Mol Pharm. 2004 Jan 12;1(1):49-56.
78 Uptake of enalapril and expression of organic anion transporting polypeptide 1 in zonal, isolated rat hepatocytes. Drug Metab Dispos. 2000 Jul;28(7):801-6.
79 Identification of thyroid hormone transporters in humans: different molecules are involved in a tissue-specific manner. Endocrinology. 2001 May;142(5):2005-12.
80 Involvement of influx and efflux transport systems in gastrointestinal absorption of celiprolol. J Pharm Sci. 2009 Jul;98(7):2529-39.
81 Progestagenic effects of tibolone are target gene-specific in human endometrial cells. J Soc Gynecol Investig. 2006 Sep;13(6):459-65.
82 Tamoxifen-induced adduct formation and cell stress in human endometrial glands. Drug Metab Dispos. 2010 Jan;38(1):200-7.
83 Proposed role of the sulfotransferase/sulfatase pathway in modulating yolk steroid effects. Integr Comp Biol. 2008 Sep;48(3):419-27.
84 Interindividual variability in acetaminophen sulfation by human fetal liver: implications for pharmacogenetic investigations of drug-induced birth defects. Birth Defects Res A Clin Mol Teratol. 2008 Mar;82(3):155-65.
85 Inhibition of human phenol and estrogen sulfotransferase by certain non-steroidal anti-inflammatory agents. Curr Drug Metab. 2006 Oct;7(7):745-53.
86 Natural products isolated from Mexican medicinal plants: novel inhibitors of sulfotransferases, SULT1A1 and SULT2A1. Phytomedicine. 2001 Nov;8(6):481-8.
87 Characterization of human liver thermostable phenol sulfotransferase (SULT1A1) allozymes with 3,3',5-triiodothyronine as the substrate. J Endocrinol. 2001 Dec;171(3):525-32.
88 Crystal structure of human sulfotransferase SULT1A3 in complex with dopamine and 3'-phosphoadenosine 5'-phosphate. Biochem Biophys Res Commun. 2005 Sep 23;335(2):417-23.
89 Sulfation of benzyl alcohol by the human cytosolic sulfotransferases (SULTs): a systematic analysis. J Appl Toxicol. 2016 Sep;36(9):1090-4.
90 The 2.7 A resolution structure of the glycopeptide sulfotransferase Teg14. Acta Crystallogr D Biol Crystallogr. 2010 Dec;66(Pt 12):1278-86.
91 Functional defect caused by the 4544G>A SNP in ABCC2: potential impact for drug cellular disposition. Pharmacogenet Genomics. 2011 Dec;21(12):884-93. doi: 10.1097/FPC.0b013e32834d672b.
92 Role of multidrug resistance protein 2 (MRP2, ABCC2) in alkylating agent detoxification: MRP2 potentiates glutathione S-transferase A1-1-mediated resistance to chlorambucil cytotoxicity. J Pharmacol Exp Ther. 2004 Jan;308(1):260-7. doi: 10.1124/jpet.103.057729. Epub 2003 Oct 20.
93 MRP2 (ABCC2) transports taxanes and confers paclitaxel resistance and both processes are stimulated by probenecid. Int J Cancer. 2005 Sep 20;116(5):824-9. doi: 10.1002/ijc.21013.
94 Association of genetic polymorphisms in SLCO1B3 and ABCC2 with docetaxel-induced leukopenia. Cancer Sci. 2008 May;99(5):967-72.
95 Methotrexate normalizes up-regulated folate pathway genes in rheumatoid arthritis. Arthritis Rheum. 2013 Nov;65(11):2791-802.
96 In vitro study of transporters involved in intestinal absorption of inorganic arsenic. Chem Res Toxicol. 2012 Feb 20;25(2):446-53. doi: 10.1021/tx200491f. Epub 2012 Jan 26.
97 Co-encapsulation of chrysophsin-1 and epirubicin in PEGylated liposomes circumvents multidrug resistance in HeLa cells. Chem Biol Interact. 2015 Dec 5;242:13-23. doi: 10.1016/j.cbi.2015.08.023. Epub 2015 Sep 1.
98 Evaluation of drug transporters' significance for multidrug resistance in head and neck squamous cell carcinoma. Head Neck. 2011 Jul;33(7):959-68. doi: 10.1002/hed.21559. Epub 2010 Aug 24.
99 Gene expression analysis of precision-cut human liver slices indicates stable expression of ADME-Tox related genes. Toxicol Appl Pharmacol. 2011 May 15;253(1):57-69.
100 Differential regulation of sinusoidal and canalicular hepatic drug transporter expression by xenobiotics activating drug-sensing receptors in primary human hepatocytes. Drug Metab Dispos. 2006 Oct;34(10):1756-63. doi: 10.1124/dmd.106.010033. Epub 2006 Jul 12.
101 Effect of organic anion-transporting polypeptide 1B1 (OATP1B1) polymorphism on the single- and multiple-dose pharmacokinetics of enalapril in healthy Chinese adult men. Clin Ther. 2011 May;33(5):655-63. doi: 10.1016/j.clinthera.2011.04.018.
102 Differential interaction of 3-hydroxy-3-methylglutaryl-coa reductase inhibitors with ABCB1, ABCC2, and OATP1B1. Drug Metab Dispos. 2005 Apr;33(4):537-46.
103 Omics-based responses induced by bosentan in human hepatoma HepaRG cell cultures. Arch Toxicol. 2018 Jun;92(6):1939-1952.
104 Polymorphic organic anion transporting polypeptide 1B1 is a major determinant of repaglinide pharmacokinetics. Clin Pharmacol Ther. 2005 Jun;77(6):468-78. doi: 10.1016/j.clpt.2005.01.018.
105 SLC19A1, SLC46A1 and SLCO1B1 polymorphisms as predictors of methotrexate-related toxicity in Portuguese rheumatoid arthritis patients. Toxicol Sci. 2014 Nov;142(1):196-209. doi: 10.1093/toxsci/kfu162. Epub 2014 Aug 14.
106 SLCO1B1 variants and statin-induced myopathy--a genomewide study. N Engl J Med. 2008 Aug 21;359(8):789-99.
107 Transport of fluorescent chenodeoxycholic acid via the human organic anion transporters OATP1B1 and OATP1B3. J Lipid Res. 2006 Jun;47(6):1196-202.
108 Transcellular movement of hydroxyurea is mediated by specific solute carrier transporters. Exp Hematol. 2011 Apr;39(4):446-56.
109 Severe toxicities after irinotecan-based chemotherapy in a patient with lung cancer: a homozygote for the SLCO1B1*15 allele. Ther Drug Monit. 2007 Oct;29(5):666-8. doi: 10.1097/FTD.0b013e3181357364.
110 Germline genetic variation in an organic anion transporter polypeptide associated with methotrexate pharmacokinetics and clinical effects. J Clin Oncol. 2009 Dec 10;27(35):5972-8.
111 Screening of a chemical library reveals novel PXR-activating pharmacologic compounds. Toxicol Lett. 2015 Jan 5;232(1):193-202. doi: 10.1016/j.toxlet.2014.10.009. Epub 2014 Oct 16.
112 Induction of PXR-mediated metabolism by beta-carotene. Biochim Biophys Acta. 2005 May 30;1740(2):162-9. doi: 10.1016/j.bbadis.2004.11.013. Epub 2004 Dec 8.
113 Lignans, bacteriocides and organochlorine compounds activate the human pregnane X receptor (PXR). Toxicol Appl Pharmacol. 2005 Dec 1;209(2):123-33. doi: 10.1016/j.taap.2005.03.015.
114 Identification and validation of novel human pregnane X receptor activators among prescribed drugs via ligand-based virtual screening. Drug Metab Dispos. 2011 Feb;39(2):337-44. doi: 10.1124/dmd.110.035808. Epub 2010 Nov 10.
115 Identification of HMG-CoA reductase inhibitors as activators for human, mouse and rat constitutive androstane receptor. Drug Metab Dispos. 2005 Jul;33(7):924-9.
116 The relative role of CYP3A4 and CYP3A5 in eplerenone metabolism. Toxicol Lett. 2019 Oct 15;315:9-13.
117 Characterization of the structural determinants required for potent mechanism-based inhibition of human cytochrome P450 1A1 by cannabidiol. Chem Biol Interact. 2014 May 25;215:62-8.
118 Retinoids activate the RXR/SXR-mediated pathway and induce the endogenous CYP3A4 activity in Huh7 human hepatoma cells. Toxicol Sci. 2006 Jul;92(1):51-60.
119 The novel azole R126638 is a selective inhibitor of ergosterol synthesis in Candida albicans, Trichophyton spp., and Microsporum canis. Antimicrob Agents Chemother. 2004 Sep;48(9):3272-8.
120 Application of higher throughput screening (HTS) inhibition assays to evaluate the interaction of antiparasitic drugs with cytochrome P450s. Drug Metab Dispos. 2001 Jan;29(1):30-5.
121 Cetirizine and loratadine-based antihistamines with 5-lipoxygenase inhibitory activity. Bioorg Med Chem Lett. 2004 Nov 15;14(22):5591-4.
122 Mechanism-based inactivation of CYP3A by HIV protease inhibitors. J Pharmacol Exp Ther. 2005 Feb;312(2):583-91.
123 Studies of the toxicological potential of capsinoids, XIII: inhibitory effects of capsaicin and capsinoids on cytochrome P450 3A4 in human liver microsomes. Int J Toxicol. 2010 Mar;29(2 Suppl):22S-6S.
124 Investigation of the effects of axitinib on the pharmacokinetics of loperamide and its main metabolite N-demethylated loperamide in rats by UPLC-MS/MS. Chem Biol Interact. 2019 Sep 1;310:108744. doi: 10.1016/j.cbi.2019.108744. Epub 2019 Jul 9.
125 Gene expression profiling of leukemia T-cells resistant to methotrexate and 7-hydroxymethotrexate reveals alterations that preserve intracellular levels of folate and nucleotide biosynthesis. Biochem Pharmacol. 2009 Apr 15;77(8):1410-7.
126 Drug sensitivity and drug resistance profiles of human intrahepatic cholangiocarcinoma cell lines. World J Gastroenterol. 2005 May 14;11(18):2748-53. doi: 10.3748/wjg.v11.i18.2748.
127 Adaptive homeostasis of the vitamin D-vitamin D nuclear receptor axis in 8-methoxypsoralen-induced hepatotoxicity. Toxicol Appl Pharmacol. 2019 Jan 1;362:150-158. doi: 10.1016/j.taap.2018.11.002. Epub 2018 Nov 10.
128 Cannabidiol induces antioxidant pathways in keratinocytes by targeting BACH1. Redox Biol. 2020 Jan;28:101321. doi: 10.1016/j.redox.2019.101321. Epub 2019 Sep 5.
129 Estrogen regulation in human breast cancer cells of new downstream gene targets involved in estrogen metabolism, cell proliferation and cell transformation. J Mol Endocrinol. 2004 Apr;32(2):397-414.
130 Global gene expression analysis reveals differences in cellular responses to hydroxyl- and superoxide anion radical-induced oxidative stress in caco-2 cells. Toxicol Sci. 2010 Apr;114(2):193-203. doi: 10.1093/toxsci/kfp309. Epub 2009 Dec 31.
131 Differential regulation of the human MRP2 and MRP3 gene expression by glucocorticoids. J Steroid Biochem Mol Biol. 2005 Aug;96(3-4):229-34. doi: 10.1016/j.jsbmb.2005.03.004.
132 Induction of multidrug resistance proteins MRP1 and MRP3 and gamma-glutamylcysteine synthetase gene expression by nonsteroidal anti-inflammatory drugs in human colon cancer cells. Biochem Biophys Res Commun. 2002 Feb 8;290(5):1427-33. doi: 10.1006/bbrc.2002.6367.
133 Activation of nuclear factor-kappa B pathway by simvastatin and RhoA silencing increases doxorubicin cytotoxicity in human colon cancer HT29 cells. Mol Pharmacol. 2008 Aug;74(2):476-84.
134 Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development. Toxicol Sci. 2010 Dec; 118(2):485-500.
135 Early identification of clinically relevant drug interactions with the human bile salt export pump (BSEP/ABCB11). Toxicol Sci. 2013 Dec;136(2):328-43.
136 Evaluating the Role of Multidrug Resistance Protein 3 (MDR3) Inhibition in Predicting Drug-Induced Liver Injury Using 125 Pharmaceuticals. Chem Res Toxicol. 2017 May 15;30(5):1219-1229. doi: 10.1021/acs.chemrestox.7b00048. Epub 2017 May 4.
137 A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development. Toxicol Sci. 2013 Nov;136(1):216-41.
138 Molecular mechanisms of hepatotoxic cholestasis by clavulanic acid: Role of NRF2 and FXR pathways. Food Chem Toxicol. 2021 Dec;158:112664. doi: 10.1016/j.fct.2021.112664. Epub 2021 Nov 9.
139 The contribution of methotrexate exposure and host factors on transcriptional variance in human liver. Toxicol Sci. 2007 Jun;97(2):582-94.
140 Pharmacotoxicology of clinically-relevant concentrations of obeticholic acid in an organotypic human hepatocyte system. Toxicol In Vitro. 2017 Mar;39:93-103.
141 Combination of retinoic acid and ursodeoxycholic acid attenuates liver injury in bile duct-ligated rats and human hepatic cells. Hepatology. 2011 Feb;53(2):548-57. doi: 10.1002/hep.24047. Epub 2010 Dec 10.
142 A transcriptome-based classifier to identify developmental toxicants by stem cell testing: design, validation and optimization for histone deacetylase inhibitors. Arch Toxicol. 2015 Sep;89(9):1599-618.
143 Lithocholic acid induction of the FGF19 promoter in intestinal cells is mediated by PXR. World J Gastroenterol. 2007 Aug 21;13(31):4230-5. doi: 10.3748/wjg.v13.i31.4230.
144 Gene Expression Regulation and Pathway Analysis After Valproic Acid and Carbamazepine Exposure in a Human Embryonic Stem Cell-Based Neurodevelopmental Toxicity Assay. Toxicol Sci. 2015 Aug;146(2):311-20. doi: 10.1093/toxsci/kfv094. Epub 2015 May 15.
145 Mitochondrial Uncoupling Induces Epigenome Remodeling and Promotes Differentiation in Neuroblastoma. Cancer Res. 2023 Jan 18;83(2):181-194. doi: 10.1158/0008-5472.CAN-22-1029.
146 Global molecular effects of tocilizumab therapy in rheumatoid arthritis synovium. Arthritis Rheumatol. 2014 Jan;66(1):15-23.
147 The methyl transferase PRMT1 functions as co-activator of farnesoid X receptor (FXR)/9-cis retinoid X receptor and regulates transcription of FXR responsive genes. Mol Pharmacol. 2005 Aug;68(2):551-8. doi: 10.1124/mol.105.012104. Epub 2005 May 23.
148 Increased sensitivity for troglitazone-induced cytotoxicity using a human in vitro co-culture model. Toxicol In Vitro. 2009 Oct;23(7):1387-95.
149 Robustness testing and optimization of an adverse outcome pathway on cholestatic liver injury. Arch Toxicol. 2020 Apr;94(4):1151-1172. doi: 10.1007/s00204-020-02691-9. Epub 2020 Mar 10.
150 Species-specific mechanisms for cholesterol 7alpha-hydroxylase (CYP7A1) regulation by drugs and bile acids. Arch Biochem Biophys. 2005 Feb 1;434(1):75-85.
151 A novel bile acid-activated vitamin D receptor signaling in human hepatocytes. Mol Endocrinol. 2010 Jun;24(6):1151-64.
152 Transcriptomic analysis of untreated and drug-treated differentiated HepaRG cells over a 2-week period. Toxicol In Vitro. 2015 Dec 25;30(1 Pt A):27-35.
153 Dysregulation of retinoic acid receptor diminishes hepatocyte permissiveness to hepatitis B virus infection through modulation of sodium taurocholate cotransporting polypeptide (NTCP) expression. J Biol Chem. 2015 Feb 27;290(9):5673-84. doi: 10.1074/jbc.M114.602540. Epub 2014 Dec 30.
154 Comparison of HepG2 and HepaRG by whole-genome gene expression analysis for the purpose of chemical hazard identification. Toxicol Sci. 2010 May;115(1):66-79.
155 Regulation of hepatic drug transporter activity and expression by organochlorine pesticides. J Biochem Mol Toxicol. 2014 Mar;28(3):119-28.
156 Integrative omics data analyses of repeated dose toxicity of valproic acid in vitro reveal new mechanisms of steatosis induction. Toxicology. 2018 Jan 15;393:160-170.
157 A toxicogenomic approach to drug-induced phospholipidosis: analysis of its induction mechanism and establishment of a novel in vitro screening system. Toxicol Sci. 2005 Feb;83(2):282-92.
158 Arsenite and cadmium promote the development of mammary tumors. Carcinogenesis. 2020 Jul 14;41(7):1005-1014. doi: 10.1093/carcin/bgz176.
159 Time series analysis of oxidative stress response patterns in HepG2: a toxicogenomics approach. Toxicology. 2013 Apr 5;306:24-34.
160 Determination of phospholipidosis potential based on gene expression analysis in HepG2 cells. Toxicol Sci. 2007 Mar;96(1):101-14.
161 Farnesoid X receptor induces murine scavenger receptor Class B type I via intron binding. PLoS One. 2012;7(4):e35895. doi: 10.1371/journal.pone.0035895. Epub 2012 Apr 23.
162 Comparison of phenotypic and transcriptomic effects of false-positive genotoxins, true genotoxins and non-genotoxins using HepG2 cells. Mutagenesis. 2011 Sep;26(5):593-604.
163 Transcriptional and Metabolic Dissection of ATRA-Induced Granulocytic Differentiation in NB4 Acute Promyelocytic Leukemia Cells. Cells. 2020 Nov 5;9(11):2423. doi: 10.3390/cells9112423.
164 Rifampin Regulation of Drug Transporters Gene Expression and the Association of MicroRNAs in Human Hepatocytes. Front Pharmacol. 2016 Apr 26;7:111.
165 Large-scale in silico and microarray-based identification of direct 1,25-dihydroxyvitamin D3 target genes. Mol Endocrinol. 2005 Nov;19(11):2685-95.
166 Endoplasmic reticulum stress and MAPK signaling pathway activation underlie leflunomide-induced toxicity in HepG2 Cells. Toxicology. 2017 Dec 1;392:11-21.
167 Calcium pantothenate modulates gene expression in proliferating human dermal fibroblasts. Exp Dermatol. 2009 Nov;18(11):969-78. doi: 10.1111/j.1600-0625.2009.00884.x. Epub 2009 Apr 8.
168 Similarities and differences between two modes of antagonism of the thyroid hormone receptor. ACS Chem Biol. 2011 Oct 21;6(10):1096-106.
169 Expression and regulation of the bile acid transporter, OSTalpha-OSTbeta in rat and human intestine and liver. Biopharm Drug Dispos. 2009 Jul;30(5):241-58.
170 Integrating multiple omics to unravel mechanisms of Cyclosporin A induced hepatotoxicity in vitro. Toxicol In Vitro. 2015 Apr;29(3):489-501.
171 Ursodeoxycholic acid but not tauroursodeoxycholic acid inhibits proliferation and differentiation of human subcutaneous adipocytes. PLoS One. 2013 Dec 3;8(12):e82086. doi: 10.1371/journal.pone.0082086. eCollection 2013.
172 Identification of mechanisms of action of bisphenol a-induced human preadipocyte differentiation by transcriptional profiling. Obesity (Silver Spring). 2014 Nov;22(11):2333-43.
173 Bromodomain-containing protein 4 (BRD4) regulates RNA polymerase II serine 2 phosphorylation in human CD4+ T cells. J Biol Chem. 2012 Dec 14;287(51):43137-55.
174 Air pollution and DNA methylation alterations in lung cancer: A systematic and comparative study. Oncotarget. 2017 Jan 3;8(1):1369-1391. doi: 10.18632/oncotarget.13622.
175 Quantitative high-throughput profiling of environmental chemicals and drugs that modulate farnesoid X receptor. Sci Rep. 2014 Sep 26;4:6437. doi: 10.1038/srep06437.
176 The farnesoid X receptor FXRalpha/NR1H4 acquired ligand specificity for bile salts late in vertebrate evolution. Am J Physiol Regul Integr Comp Physiol. 2007 Sep;293(3):R1400-9. doi: 10.1152/ajpregu.00781.2006. Epub 2007 Jun 13.
177 Investigation of imatinib and other approved drugs as starting points for antidiabetic drug discovery with FXR modulating activity. Biochem Pharmacol. 2012 Jun 15;83(12):1674-81. doi: 10.1016/j.bcp.2012.02.027. Epub 2012 Mar 7.
178 Organochloride pesticides modulated gut microbiota and influenced bile acid metabolism in mice. Environ Pollut. 2017 Jul;226:268-276.
179 Repression of hepatocyte nuclear factor 4 alpha by AP-1 underlies dyslipidemia associated with retinoic acid. J Lipid Res. 2019 Apr;60(4):794-804. doi: 10.1194/jlr.M088880. Epub 2019 Feb 1.
180 Physiological and toxicological transcriptome changes in HepG2 cells exposed to copper. Physiol Genomics. 2009 Aug 7;38(3):386-401.
181 Identification of two novel genes SLC15A2 and SLCO1B3 associated with maintenance dose variability of warfarin in a Chinese population. Sci Rep. 2017 Dec 12;7(1):17379. doi: 10.1038/s41598-017-17731-1.
182 Involvement of multiple efflux transporters in hepatic disposition of fexofenadine. Mol Pharmacol. 2008 May;73(5):1474-83.
183 Expression of drug transporters and drug metabolizing enzymes in the bladder urothelium in man and affinity of the bladder spasmolytic trospium chloride to transporters likely involved in its pharmacokinetics. Mol Pharm. 2015 Jan 5;12(1):171-8.
184 Primary Human Hepatocyte Spheroids as Tools to Study the Hepatotoxic Potential of Non-Pharmaceutical Chemicals. Int J Mol Sci. 2021 Oct 12;22(20):11005. doi: 10.3390/ijms222011005.
185 Prenatal arsenic exposure and the epigenome: identifying sites of 5-methylcytosine alterations that predict functional changes in gene expression in newborn cord blood and subsequent birth outcomes. Toxicol Sci. 2015 Jan;143(1):97-106. doi: 10.1093/toxsci/kfu210. Epub 2014 Oct 10.
186 Transcriptional profiling suggests that Nevirapine and Ritonavir cause drug induced liver injury through distinct mechanisms in primary human hepatocytes. Chem Biol Interact. 2016 Aug 5;255:31-44.
187 MS4A3-HSP27 target pathway reveals potential for haematopoietic disorder treatment in alimentary toxic aleukia. Cell Biol Toxicol. 2023 Feb;39(1):201-216. doi: 10.1007/s10565-021-09639-4. Epub 2021 Sep 28.
188 Retinoic acid and its 4-oxo metabolites are functionally active in human skin cells in vitro. J Invest Dermatol. 2005 Jul;125(1):143-53.
189 Steroidogenic gene expression in H295R cells and the human adrenal gland: adrenotoxic effects of lindane in vitro. J Appl Toxicol. 2006 Nov-Dec;26(6):484-92.
190 Integrated 'omics analysis reveals new drug-induced mitochondrial perturbations in human hepatocytes. Toxicol Lett. 2018 Jun 1;289:1-13.
191 Differential gene expression in human hepatocyte cell lines exposed to the antiretroviral agent zidovudine. Arch Toxicol. 2014 Mar;88(3):609-23. doi: 10.1007/s00204-013-1169-3. Epub 2013 Nov 30.
192 Transcriptomics hit the target: monitoring of ligand-activated and stress response pathways for chemical testing. Toxicol In Vitro. 2015 Dec 25;30(1 Pt A):7-18.
193 Identification of vitamin D3 target genes in human breast cancer tissue. J Steroid Biochem Mol Biol. 2016 Nov;164:90-97.
194 Prenatal ethanol exposure increases maternal bile acids through placental transport pathway. Toxicology. 2021 Jun 30;458:152848. doi: 10.1016/j.tox.2021.152848. Epub 2021 Jul 2.